Article

Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy

2021-10-01

Abstract excerpt

Chimeric antigen receptor (CAR) T-cell therapy is potentially an effective targeted immunotherapy for glioblastoma, yet there is presently little known about the efficacy of CAR T-cell treatment when combined with the widely used anti-inflammatory and immunosuppressant glucocorticoid, dexamethasone. Here we present a mathematical model-based analysis of three patient-derived glioblastoma cell lines treated in vit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9234ca4a-7a17-59b0-8b83-d2a50f7f8a0e
DOI: 10.1101/2021.10.01.462697

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacyDOI 10.1101/2021.10.01.462697Read

The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapySemantic proximity Read

A Mathematical Model for On-Target Off-Tumor Effect of CAR-T Cells on GliomasSemantic proximity Read

Stochastic modeling suggests that noise reduces differentiation efficiency by inducing a heterogeneous drug response in glioma differentiation therapy.Semantic proximity Read

CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different amplitude.Semantic proximity Read

Threshold-awareness in adaptive cancer therapySemantic proximity Read

A comparison of mutation and amplification-driven resistance mechanisms and their impacts on tumor recurrence.Semantic proximity Read

A Minimal Model Framework for Robust CAR-T Cell and Oncolytic Virus Combination TherapySemantic proximity Read

Mathematical modeling reveals a critical role for cyclin D1 dynamics in phenotype switching during glioma differentiation.Semantic proximity Read

Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression.Semantic proximity Read

Computational modelling of CAR T-cell therapy: from cellular kinetics to patient-level predictionsSemantic proximity Read

Optimal control of Multiple Myeloma assuming drug evasion and off-target effectsSemantic proximity Read

Three-Compartment Model of CAR T-cell ImmunotherapySemantic proximity Read